Scientific Reports (Jun 2017)

NAD+ augmentation ameliorates acute pancreatitis through regulation of inflammasome signalling

  • AiHua Shen,
  • Hyung-Jin Kim,
  • Gi-Su Oh,
  • Su-Bin Lee,
  • Seung Hoon Lee,
  • Arpana Pandit,
  • Dipendra Khadka,
  • Seong-Kyu Choe,
  • Sung Chul Kwak,
  • Sei-Hoon Yang,
  • Eun-Young Cho,
  • Hyun-Seok Kim,
  • Hail Kim,
  • Raekil Park,
  • Tae Hwan Kwak,
  • Hong-Seob So

DOI
https://doi.org/10.1038/s41598-017-03418-0
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Acute pancreatitis (AP) is a complicated disease without specific drug therapy. The cofactor nicotinamide adenine dinucleotide (NAD+) is an important regulator of cellular metabolism and homeostasis. However, it remains unclear whether modulation of NAD+ levels has an impact on caerulein-induced AP. Therefore, in this study, we investigated the effect of increased cellular NAD+ levels on caerulein-induced AP. We demonstrated for the first time that the activities and expression of SIRT1 were suppressed by reduction of intracellular NAD+ levels and the p53-microRNA-34a pathway in caerulein-induced AP. Moreover, we confirmed that the increase of cellular NAD+ by NQO1 enzymatic action using the substrate β-Lapachone suppressed caerulein-induced AP with down-regulating TLR4-mediated inflammasome signalling, and thereby reducing the inflammatory responses and pancreatic cell death. These results suggest that pharmacological stimulation of NQO1 could be a promising therapeutic strategy to protect against pathological tissue damage in AP.